

Gilles R Dagenais

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4554308/gilles-r-dagenais-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

43
papers

8,445
citations

26
h-index

44
g-index

44
ext. papers

10,516
ext. citations

18.2
avg. IF

4.85
L-index

#	Paper	IF	Citations
43	Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. <i>European Heart Journal</i> , 2021 , 42, 2565-2573	9.5	7
42	Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease. <i>Heart</i> , 2021 , 107, 1130-1137	5.1	0
41	Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Trial. <i>Stroke</i> , 2021 , 52, 2494-2501	6.7	1
40	Effectiveness of a web-based computer-tailored intervention promoting physical activity for adults from Quebec City: a randomized controlled trial. <i>Health Psychology and Behavioral Medicine</i> , 2020 , 8, 601-622	2.2	1
39	Association of nut intake with risk factors, cardiovascular disease, and mortality in 16 countries from 5 continents: analysis from the Prospective Urban and Rural Epidemiology (PURE) study. <i>American Journal of Clinical Nutrition</i> , 2020 , 112, 208-219	7	11
38	Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trial: a post hoc analysis. <i>Cardiovascular Diabetology</i> , 2020 , 19, 199	8.7	3
37	Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy. <i>Stroke</i> , 2020 , 51, 2901-2909	6.7	5
36	Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study. <i>Lancet, The</i> , 2020 , 395, 785-794	40	218
35	Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1519-1528	15.1	17
34	Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. <i>Lancet, The</i> , 2019 , 394, 121-130	40	917
33	Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. <i>Lancet, The</i> , 2019 , 394, 131-138	40	228
32	Effects of basal insulin glargine and omega-3 on lower limb arterial disease outcome in patients with dysglycaemia: An analysis of the Outcome Reduction with an Initial Glargine INTERvention (ORIGIN) trial. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1502-1505	6.7	1
31	Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial. <i>International Journal of Stroke</i> , 2019 , 14, 270-281	6.3	9
30	Effects of blood pressure and lipid lowering on cognition: Results from the HOPE-3 study. <i>Neurology</i> , 2019 , 92, e1435-e1446	6.5	34
29	Effects of Lipid-Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE-3 Trial. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	1
28	Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study. <i>Lancet Diabetes and Endocrinology, the</i> , 2018 , 6, 798-808	18.1	66
27	Impact of treatment strategies on outcomes in patients with stable coronary artery disease and type 2 diabetes mellitus according to presenting angina severity: A pooled analysis of three federally-funded randomized trials. <i>Atherosclerosis</i> , 2018 , 277, 186-194	3.1	6

26	Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 42-49	6.7	121
25	Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018 , 391, 205-218	4.0	204
24	Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018 , 391, 219-229	4.0	414
23	Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 1027-1035 ⁹⁷	3.8	1035
22	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017 , 377, 1319-1330	59.2	1122
21	Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants\Baseline Characteristics. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 311-8	3.8	21
20	Variations in Diabetes Prevalence in Low-, Middle-, and High-Income Countries: Results From the Prospective Urban and Rural Epidemiological Study. <i>Diabetes Care</i> , 2016 , 39, 780-7	14.6	104
19	Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016 , 374, 2009-20	59.2	382
18	Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016 , 374, 2021-31	59.2	440
17	Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016 , 374, 2032-43	59.2	199
16	Healthy eating and reduced risk of cognitive decline: A cohort from 40 countries. <i>Neurology</i> , 2015 , 84, 2258-65	6.5	44
15	Rationale, design and baseline characteristics of a randomized controlled trial of a web-based computer-tailored physical activity intervention for adults from Quebec City. <i>BMC Public Health</i> , 2015 , 15, 1038	4.1	6
14	Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology/Canadian Society of Cardiac Surgery position statement on revascularization--multivessel coronary artery disease. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 1482-91	3.8	40
13	Incidental magnetic resonance diffusion-weighted imaging-positive lesions are rare in neurologically asymptomatic community-dwelling adults. <i>Stroke</i> , 2014 , 45, 2115-7	6.7	20
12	Prognostic impact of the presence and absence of angina on mortality and cardiovascular outcomes in patients with type 2 diabetes and stable coronary artery disease: results from the BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) trial. <i>Journal of the American College of Cardiology</i> , 2013 , 61, 702-11	15.1	36
11	n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. <i>New England Journal of Medicine</i> , 2012 , 367, 309-18	59.2	659
10	Basal insulin and cardiovascular and other outcomes in dysglycemia. <i>New England Journal of Medicine</i> , 2012 , 367, 319-28	59.2	1138
9	Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. <i>Lancet, The</i> , 2011 , 378, 1231-43	4.0	627

8	Effects of optimal medical treatment with or without coronary revascularization on angina and subsequent revascularizations in patients with type 2 diabetes mellitus and stable ischemic heart disease. <i>Circulation</i> , 2011 , 123, 1492-500	16.7	88
7	Vascular protection: telmisartan in the ONTARGET Trial Programme. <i>European Heart Journal Supplements</i> , 2009 , 11, F47-F53	1.5	1
6	Assessment of activity status and survival according to the Canadian Cardiovascular Society angina classification. <i>Canadian Journal of Cardiology</i> , 2009 , 25, e225-31	3.8	33
5	Impact of ramipril on the circadian periodicity of acute myocardial infarction. <i>American Journal of Cardiology</i> , 2006 , 98, 758-60	3	9
4	Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. <i>Lancet, The</i> , 2006 , 368, 581-8	4 ⁰	386
3	Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. <i>American Heart Journal</i> , 2005 , 149, 54-60	4.9	252
2	Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study. <i>Circulation</i> , 2001 , 104, 522-6	16.7	157
1	Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the QuBec cardiovascular study. <i>Circulation</i> , 1996 , 94, 273-8	16.7	320